Soleus Capital Management, L.P. Liquidia Corp Transaction History

Soleus Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.77 - $12.19 $952,049 - $2.01 Million	-165,000 Reduced 94.29%	10,000 $120,000
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $1.16 Million - $1.73 Million	175,000 New	175,000 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$3.37 - $7.55 $989,044 - $2.22 Million	-293,485 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.14 - $7.38 $318,680 - $457,560	62,000 Added 26.78%	293,485 $2.11 Million
Q4 2021 Feb 14, 2022	BUY	$2.71 - $5.17 $627,324 - $1.2 Million	231,485 New	231,485 $1.13 Million

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.